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Marketing in the lay media and prescriptions of
terbinafine in primary care: Dutch cohort study
Geert W ’t Jong, Bruno H Ch Stricker, Miriam C J M Sturkenboom
In May 2000 in the Netherlands, the manufacturer of
terbinafine, Novartis, started a nationwide “information
campaign” which included television advertisements
advising people with onychomycosis to visit their
general practitioner. The Dutch Society of General Prac-
titioners objected to this campaign as an unnecessary
focus on an unimportant health problem.1 In the
Netherlands, terbinafine and itraconazole are available
as oral treatments for onychomycosis, but the Society’s
guidelines recommend terbinafine.2 3 In May 2002, a
Dutch court decided that Novartis’s campaign did not
violate laws prohibiting advertising of prescription drugs
as neither Novartis nor terbinafine were specifically
named1; however,Novartis stopped the campaign in July
2002.We studied the changes in rates of prescriptions of
oral terbinafine and itraconazole and the consultation
rate before and after the start of the campaign.
Participants, methods, and results
We retrieved all data from the integrated primary care
information project—a Dutch research database for
general practice—with data from a group of 150
general practitioners.4 To determine rates of prescrip-
tion of terbinafine and itraconazole for onychomyco-
sis, we counted all prescriptions (first and repeat)
written for that specific indication before (1996-9) and
during the campaign (2000-2) and divided these by the
amount of person time in the population. We also
assessed the consultation rate for new onychomycosis.
The source population comprised 470 775 patients
(239 154; 50.8% males) with a total follow up of 1.5 mil-
lion person years. During the study period, general
practitioners issued 11 930 prescriptions for terbinafine
and 10 014 prescriptions for itraconazole for ony-
chomycosis. Before the television campaign (1996-9),
the overall prescription rates of terbinafine and
itraconazole were 6.50 (95% confidence interval 6.33 to
6.66) and 6.84 (6.67 to7.01) prescriptions per 1000 per-
son years. The prescription rate of terbinafine increased
from 7.7 in the month before to 15.2 (13.5 to 16.9) in the
month after the launch of the campaign, and was 10.26
(9.99 to 10.53) per 1000 person years in the entire
period during the campaign (2000-2). Conversely,
during the campaign the prescription rate of itracona-
zole decreased to 6.07 (5.86 to 6.28) (figure). The consul-
tation rate for new onychomycosis increased from 5.9
(5.6 to 6.2) in 1999 to a peak of 8.2 (7.9 to 8.6) in 2000-1
and fell to 4.9 (4.6 to 5.1) per 1000 person years in 2002.
Comment
The rate of prescription of terbinafine increased
considerably after the launch of an advertising
campaign about onychomycosis in the Netherlands;
the rate of prescription of itraconazole slightly
decreased. This seems surprising for a campaign in the
lay press which did not specifically mention terbin-
afine. That the campaign was successful in motivating
people to seek care for onychomycosis is strongly sug-
gested by the concurrent increase in the consultation
rate for onychomycosis. Since terbinafine is recom-
mended in prescribing standards, the stimulating effect
of anonymous advertising in the lay press on prescrip-
tions of terbinafine was predictable. Novartis’s cam-
paign, therefore, was not beneficial to the prescription
of drugs used for onychomycosis in general, as the
company claimed, but specifically beneficial for terbin-
afine. After the campaign was stopped in July 2002,
rates of consultations and prescriptions dropped again.
The effects on work load in primary care of the lay
media marketing medicinal products for cosmetic
indications which cannot be treated with over the
counter drugs should not be underestimated. Several
synchronous campaigns like this would cause a serious
adverse impact on general practitioners’ workloads
and costs. This may affect patients who need care for
more serious problems.
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